RefluxStop U.S. Launch Draws 120+ Surgeons at AFS 2026

The U.S. surgical treatment landscape for GERD is poised for disruption as Implantica claims its RefluxStop device offers a non-encircling alternative to traditional fundoplication and magnetic sphincter augmentation. With FDA PMA in hand, the September 29, 2026 AFS launch drew 120+ surgeons and gastroenterologists, signaling strong early Key Opinion Leader interest—but hospital adoption, CPT coding, and payer coverage remain unproven. For gastroenterologists, foregut surgeons, and health systems evaluating next-generation anti-reflux interventions, this launch marks the start of a critical real-world evidence cycle.

Vaduz, Liechtenstein-based medical device company Implantica AG announced on September 29, 2026, that its RefluxStop anti-reflux implant received an "enthusiastic reception" from leading surgeons and gastroenterologists at the American Foregut Society (AFS) 2026 Annual Meeting in Washington, D.C. The announcement, distributed via PRNewswire, marks the official U.S. market launch kickoff for RefluxStop following what the company describes as a recent FDA Premarket Approval (PMA). While the event generated strong on-site interest—including a standing-room-only panel of more than 120 surgeons, gastroenterologists, and other experts—it is important to recognize that all details come from a company press release, and commercial or adoption claims should be treated as forward-looking and unaudited.

“

market launch kickoff for RefluxStop following what the company describes as a recent FDA Premarket Approval (PMA).

The RefluxStop device targets gastroesophageal reflux disease (GERD), a chronic condition that the company states affects approximately 78 million Americans. Traditional anti-reflux surgeries such as Nissen fundoplication physically wrap the upper stomach around the esophagus to reinforce the lower esophageal sphincter. While effective for many patients, these encircling procedures can lead to difficult postoperative side effects including dysphagia, gas bloat, and the inability to belch or vomit. RefluxStop takes a different approach: its non-encircling design aims to restore and maintain the body's natural anatomy and physiology, leaving the esophagus untouched rather than wrapping it. Implantica argues this mechanism reduces the common side-effect burden associated with traditional fundoplication and magnetic sphincter augmentation devices.

Clinical credibility for RefluxStop is anchored in what Implantica describes as five-year clinical study results and real-world experience across more than 60 centers in Europe. AFS past president Dr. John Lipham, Chief of the Division of Upper GI and General Surgery at the Keck School of Medicine of USC, moderated the launch panel and called the FDA PMA "a significant milestone and inflection point in the evolution of GERD treatment over the past 70+ years." This quote, while influential, is sourced directly from the press release and reflects the selected moderator's framing rather than independent clinical consensus. The AFS launch represents four consecutive years of scientific engagement by Implantica, indicating a deliberate strategy to build U.S. Key Opinion Leader support ahead of commercialization.

From a market perspective, the U.S. GERD treatment universe is large but highly fragmented. Proton pump inhibitors (PPIs) remain first-line therapy for most of the 78 million symptomatic Americans, leaving surgical and device-based interventions for a smaller refractory subset. Within that procedural niche, existing options include laparoscopic fundoplication, the LINX magnetic sphincter augmentation system from Ethicon/Johnson & Johnson, transoral incisionless fundoplication, and emerging neuromodulation devices. RefluxStop's non-encircling philosophy could differentiate it if U.S. surgeons perceive a meaningful reduction in side effects without sacrificing reflux control, but that perception will need to be proven through independent U.S. clinical experience and registry data.